Pricing and Reimbursement of Patent-Protected Medicines: Challenges and Lessons from South-Eastern Europe

ConclusionsFurther reforms aiming to develop transparent and robust national decision-making frameworks (including oversight) and build institutional HTA-related and decision-making capacity are awaited in most of SEE countries, especially the non-EU members. In non-EU SEE countries, these efforts could increase access to patent-protected medicines, which is —at the moment—very limited. The EU-member SEE countries operate more developed P&R systems but could further benefit from developing their procedures, oversight and value-for-money assessment toolbox and capacity, hence further improving the transparency and efficiency of procedures that regulate access to patent-protected medicines.
Source: Applied Health Economics and Health Policy - Category: Health Management Source Type: research